Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma

DDR1 has been identified as a cancer‐associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues. Clinically approved multi‐kinase inhibitors, such as nilotinib, inhibit DDR1‐mediated tumor growth in xenograft models, suggesting DDR1 might be a pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Yiran, Wang, Ruixue, Lai, Qinhuai, Wu, Mengdan, Wang, Yuxi, Jiang, Xiaohua, Zeng, Lishi, Zhou, Shijie, Li, Zhongping, Yang, Tinghan, Yao, Yuqin, Wu, Yangping, Yu, Lin, Fu, Yuyin, Lai, Weirong, Peng, Yujia, Lu, Ying, Zhang, Zhixiong, Guo, Cuiyu, Zhang, Guangbing, Gou, Lantu, Yang, Jinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717758/
https://www.ncbi.nlm.nih.gov/pubmed/31116512
http://dx.doi.org/10.1002/1878-0261.12520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717758/
https://www.ncbi.nlm.nih.gov/pubmed/31116512
http://dx.doi.org/10.1002/1878-0261.12520

Ejemplares similares